A highly efficient transgene knock-in technology in clinically relevant cell types-Reference-Cited by-同舟云学术

A highly efficient transgene knock-in technology in clinically relevant cell types

Published:2023-05-01 Issue: Volume: Page:
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Allen Alexander G.,Khan Samia Q.,Margulies Carrie M.,Viswanathan Ramya,Lele Swarali,Blaha Laura,Scott Sean N.,Izzo Kaitlyn M.,Gerew Alexandra,Pattali Rithu,Cochran Nadire R.,Holland Carl S.,Zhao Amy H.,Sherman Stephen E.,Jaskolka Michael C.^ORCID,Wu Meng,Wilson Aaron C.^ORCID,Sun Xiaoqi,Ciulla Dawn M.,Zhang Deric,Nelson Jacqueline D.,Zhang Peisheng^ORCID,Mazzucato Patrizia,Huang Yan,Giannoukos Georgia,Marco Eugenio^ORCID,Nehil Michael,Follit John A.,Chang Kai-Hsin,Shearman Mark S.,Wilson Christopher J.^ORCID,Zuris John A.^ORCID

Funder

Editas Medicine

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

https://www.nature.com/articles/s41587-023-01779-8.pdf

Reference62 articles.

1. Bailey, S. R. & Maus, M. V. Gene editing for immune cell therapies. Nat. Biotechnol. 37, 1425–1434 (2019).

2. Raffin, C., Vo, L. T. & Bluestone, J. A. Treg cell-based therapies: challenges and perspectives. Nat. Rev. Immunol. 20, 158–172 (2020).

3. Wilkinson, A. C., Igarashi, K. J. & Nakauchi, H. Haematopoietic stem cell self-renewal in vivo and ex vivo. Nat. Rev. Genet. 21, 541–554 (2020).